Healthcare News 5

• "Mediterranean" diet and allergies
• "Numbing Cream" have made needlesticks much less frightening and painful.
• "targeted Therapies" can have Serious side effects
• A lot of fuss about nothing
• A New Drug for Seziures, Bipolar Disorder and Pain? For Real or Wishful Thinking
• A New Eye Care Product to Capture large market share
• A way to go
• AACAP Treatment Guidelines for ADHD
• Abbott's Simcor can be expected to manage HDL and LDL well
• Abuse resistant pain treatments
• ACNE IS A PREVALENT DISEASE THAT IS NOW EASIER TO TREAT
• Acne scarring an under treated condition
• ADHD and SUD - A Complex Treatment Challenge that Cannot be Ignored
• ADHD: More bad news for stimulants are good for Strattera
• ADHD: Stimulants remain preferred drugs, but Strattera is gaining ground
• Adoption may be limited in community hospitals due to capital costs
• Advair - Increased Co-pays, UnitedHealthCare and Glaxo
• AEDs are efficacious even in the most adverse scenarios like strong electromagnetic field.
• Alba's AT-1001 in Celiac Disease
• Alcon's Aqualase System: A safer approach to cataract surgery?
• Aliskiren (Tekturna) - Renin inhibition for better hypertension control
• Alitretinoin results positive in Hand dermatitis
• Allon Therapeutics: New Approach for treatment of cognitive deficits in schizophrenia
• ALS Drug Riluzole has several important potential uses in patients with psychiatric disorders
• Altabax approved: Will Dermatologists prescribe it?
• Altabax will have good sales in the impetigo market
• Altabax(retapamulin ointment) - Alternative Therapy amidst MRSA Epidemic
• AMGEN GROWTH will continue
• AMP Battle Rages On
• AMP's Impact on Pharmacy Profits
• AMT-020 may be a revolution in porphyria treatment if confirmed in trials
• An antiallergy diet?
• An Effective Treatment for PTSD Sleep Problems
• Ancor Pro Orthodontic Anchorage System by Ortho Organizers
• Anika's Hyaluronic Acid Filler: Will Dermatologists Care?
• ANOTHER FILLER, PROS AND CONS
• Another Medicare Health Support Disease Management Program (McKesson's) Ends
• Another me-too drug?
• Another Use for Avastin
• Another Use for GSK's Bexxar
• Another Xolair?
• Anterior plating has higher fusion rate for single-disc-level procedures
• Anti-Abuse Drugs gain quicker FDA clearance, program implemented years ago.
• Antibody production to ETEC
• Antidepressants in Adolescents: To Use or Not to Use
• Antidepressants: Correcting an Over-reaction
• Anti-IL6 antibody
• Approval for overuse
• Approval of Aspheric Restor lens: Another winner for Alcon?
• Asthma Control, Poor Results are No Surprise
• Attractive and Noninvasive Therapy for a Difficult Disease
• Automatic drug delivery system through a prosthetic tooth
• Avalide, Bristol-Myers Squibb gain Favorable FDA words
• Avicena begins NIH funded phase III trial of PD-02
• Azixa for treatment of Glioblastoma Multiforme
• Basically, it's a rinse!
• Basiliximab is a Potential Therapy for Ulcerative Colitis
• Bausch & Lomb Acts Quickly to Recall Defective Contact Lens Solution
• Bausch & Lomb Voluntary Recall.
• Bausch & Lomb's building good will
• Bausch & Lomb's voluntary recall of ReNu MultiPlus has acted in the public interest.
• Behring's C1-Inhibitor Concentrate.
• Best yet to come
• Between a Rock and a Hard Place
• Beyond Monoamines: New Neurotransmitter Targets for Depression
• Beyond the Hype: RFID and e-pedigree
• Bifocal Contact Lenses-Have They Finally Achieved Success?
• Big boast for Gleevac in GIST patients
• Biotech Bail-Out of Big Pharma
• Blackouts and disinhibition are not only due to alcohol
• Boon for IDDM
• Breast is still best
• CAD for mammograms
• Can I now eat what I want?
• Canada ahead of the US in HPV vaccination
• Canada Getting on Board for Universal Gardasil (HPV vaccine) use
• Cancer immunotherapy: most efficacy is in combination with chemotherapy
• Cancer Vaccines: Way for the future, but no "gangbusters" yet!!!
• CEOs Who Lead Will Win in Wellness Too
• Ceragenin-based Contact Lens Disinfectant Solution--Is it Really a Better Mousetrap?
• Cervarix (HPV vaccine) submitted to FDA
• Cervarix has long ways to catch up with Gardasil
• CFC, HFA, and the switch in medical inhalers for asthma and COPD
• Chemotherapists should treat with Chemotherapy and Surgeons with Surgery
• Childhood cancer survivors are at increased risk of of developing sarcomas as second cancers.
• Childhood cancer survivors are at increased risk of second cancers
• Cholesterol-lowering statins and the damage of brain cells. Not all statins cross the blood-brain barrier.
• Cholinesterase Inhibitors not likely to help much in dementia
• Chronic Disease Management – Caring Doctors and Staff make the difference
• Chronic Disease Management in children
• Ciclesonide. Can we have our cake and eat it, too?
• COACH STUDY DRIVES CARE FOR CHF BACK TO PRIMARY CARE
• Collagenex Incyclinide phase 2 data released
• Combination therapy as first line therapy for hypertension
• Concerns about billing for multifocal IOLs may limit growth
• Consider "as needed" Astelin in this competitive market
• Consolidation End-Game for Wholesalers
• Contact lens misrepresentation
• Cook Vena Caval Filter Sets Standard for Retrievable Filters
• Corneal inlays: Another entrant into the presbyopia treatment wars
• Cox-2 inhibitor comeback?
• Creating a New Health Care Ecosystem
• Crestor + Zetia achieves LDL goal in 94% of patients
• Curalogic's oral immunotherapy for ragweed.
• Curcumin in cancer
• Cutting edge technology without a blade
• Cyberknife from Accuray a hit with hospitals
• Cymbalta: Propelling Eli Lilly to Higher Grounds
• Cytochroma Cta018 cream
• Cytos CYT003 in Allergic Rhinitis
• Dabigatran is the next serious competitor to Warfarin, but we have to wait for 4-5 more years!!!
• Dark chocolate--how sweet it is!
• Dasatinib/Gleevec? Whatever.
• Dendritic cell vaccine shows promise in advanced ovarian cancer but it is still far away from clinical use.
• Depocyt for lymphomatous meningitis: effective and convenient to administer
• Depomed's new formulation of effective drug will likely be useful
• depression + diabetes = death!
• Did Meteor Become a Meteorite?
• Diet can do it alone
• Disease Management Must Include Prevention
• Disease Management that is Physician/Clinic Based is only 1/2 of the Equation
• Diversion Dangers
• Do a formal clinical trial once you know it works
• Do healthplans practice medicine?
• Do Sleeping Pills Increase Parasomnias - Maybe not
• dodged a Bullet?
• Does Vagus Nerve Stimulation for Depression Really Work?
• Double edged sword
• Drug filled tooth - tongue in cheek or chic
• Drug Patent Dispute
• Duloxetine (Cymbalta) gets new FDA approval
• Duloxetine use should not change much because FDA approval for a new indication rarely means very much
• Dynavax Trials and Tribulations
• Ecluzimab reduces hemolysis and transfusions requirements in patients with PNH
• Effect of Accommodative IOL's on the Multifocal Contact Lens Industry
• Effectiveness of Medical and Behavioral Intervention in Making Needlesticks Less Painful
• ELEVESS gets CE mark approval
• Endoluminal fundoplication
• EPIX Pharmaceutical Goes After Serotonin Receptor Type 6
• Epix’s Experimental Drug PRX-07034 Shows Potential Benefit on Cognition, Obesity
• EPO for Heart Failure
• Erbitux did not add to Gemcitibine's efficacy in pancreatic cancer
• Erbitux role is limted to second and third line treatment of Colorectal cancer.
• Erythropoietin use in cancer patients: Another evidence to stick with approved indications
• Estrogen therapy and coronary heart disease.
• Ethics?
• European Union Dosing Flexibility for Remicade
• Excessive antibiotic use leads to resistance
• Exciting new therapy
• Exenatide and a TZD
• Expected
• far from new, except the wavelength
• Favorable Results of Endeavor Trail mean new competition on the horizon in coronary stent market
• FDA Approval For Medication is Important
• FDA Black Box Warnings in General
• FDA Issues Warning on Sedative-Hypnotics
• FDA warning is appropriate and will greatly impact use of ESA's
• FDA warning on sleep medications
• Figuring out Who Performs in Pay for Performance
• First to Market and Similar therapeutic classes for generics will make or break the Tentative Approval for Ranitidine Syrup ANDA
• Fish oil good for you
• Flavonoids in Chocolate Work Together, But One May Be a Medication
• Flushing rate is key to growth
• Formation of gallstaones during xenical use may be prevented
• Further Implications of Zelnorm Withdrawal
• Future Directions in the Development of Psychopharmacological Agents by Pharma
• Gadolinium agents linked to NFD
• Gardasil soon to be endorsed by all states and to be used in Europe
• Generic Drug Use Will Increase as $0.00 type Programs Incentives Increase
• Generics the Way to Go
• Glucocorticoids in RA
• Good for looks , but any health benefit?
• Good for the consumer-perhaps:bad for industry
• good from afar, far from good
• Good start...but what about inevitable new strains of H5N1?
• Government controlled drug prices >> bad for the economy >>> Socialist?
• Great in concept.....
• GSK Enters the Targeted Therapy Fray
• GSK's new vaccine has promising early results against H5N1 Inflenza strains
• Health Care Value Exchange Networks: The Next Shoe Drops
• Healthcare companies are consolidating in Montana
• Healthways 2nd Quarter Earnings - Medicare Health Support Again a Problem
• Healthways Continued Strength in the Commerical Marketplace
• Hemicraniectomy is a proven therapy, and should be made available at all stroke centers of excellence
• hidden bias
• High Dose Crestor in Combination Rx Demonstrates Dramatic LDL Lowering
• High-deductible health plans
• Hogwash
• Holy Grail?
• Home Hair Removal Devices Will Fly Out the Doors
• Hospitals Don't Quite have the Patient Safety Thing Down Pat Yet
• How different IS the Single Tooth Anesthesia System?
• How dry I am
• How far have we come with antidepressant development--or are the monoamines the answer?
• How much is a temporary fix worth?
• How much of a good thing is good?
• How will the marketing of a generic form of Ambien influence the market for sleep medications as well as current treatments for insomnia?
• HPA with ciclesonide+fluticasone
• HRT for younger women may indeed proven to be beneficial
• Humira for Psoriasis
• Hypertension an indication to disappear.
• If it lessens side effects
• If Only Flushing Were the Only Problem, Abbott Would Have a Hit
• If you had cancer would you expect to be treated? Why not for methamphetamine addiction?
• IL-7 in AIDS
• Impact of the Avastin/Lucentis controversy on the rest of ophthalmology
• Improving control of asthma
• Increasing Uncertainty over Importation
• Inhaled Fentanyl TAIFUN for breakthrough pain.
• Inhaled insulin is over-inflated
• Insurer's want to restructure doctor's pay
• intranasal antibiotics for chronic sinusitis
• Is anyone talking about the downtime?
• Is It Weight Loss or Xenical? Will Litigation Decide for Alli too?
• Is it worth the cost
• Is newer better?
• Is Non-Invasive Better Than Surgery?
• Is the FDA doing it right?
• Issue with intranasal antibiotics
• It is well known that weight loss leads to formation of gallstones
• It would certainly make more drug available and allow more strategic positioning in case of a pandemic event.
• just another HA injectable
• Kineret in diabetes
• La Jolla: No requiem for Riquent?
• Lamotrigine superior for partial epilepsy?
• Large need for vision testing according to CDC study
• Lasek following Lasik results
• Let's Not Hold Our Breath
• lifting boomers
• Lilly Pulls Ahead of the Competition with the MEMOIR Pen
• Lilly’s Strattera® for ADHD: Non-Stimulant but Non-Effective
• Lilly's Cymbalta versus Wyeth's desmethylvenlafaxine versus generic Effexor XR
• Low Profile Deal Should Help Drive Health Care Financing Reform
• Lower Dose of Risperdal Consta FDA-Approved
• Lower Dose of Risperidal® Consta®: Will it Make a Difference?!
• Lower prices may lead to greater misuse
• Lymphoseek for sentinel lymph node mapping
• Macrogenics takes a huge step forward towards a cure for diabetes
• Makes it bigger
• MAP's budenoside in children
• Marketing Strategies for Duloxetine GAD indication which can boost sales 50% or more
• Marketing to Research: "Give us these results in your next study"
• Massive Weight Loss Procedures Provide a Boost to Plastic Surgery Practices
• Medical Aesthetics Ltd.: Patients would even pay more to NOT have surgery
• Medical Aesthetics Ltd: Significant rise on male non-surgical procedures
• MedImmune's future and HMGB1
• MEDTRONIC DEVICE TO MONITOR HEARTS
• Medtronic Endeavor stent - 2nd generation stents are coming online
• Medtronic may be back again
• Mega Antidepressants-a very promising way to go
• Mega Mess
• melt away your disappointments
• Memory Pharmaceuticals' MEM 1003 Fails in Bipolar Mania Trial hope for Alzheimer's
• Men want it too
• Merck and Gilead Compete on Integrase Inhibitors
• Merrimacks RA drug
• Metformin should be in the PCOS mix.
• Microrganisms elude our control
• Mind/Body Connection
• Missed top line, but safe.
• Mixed Emotions
• Mommy Makeover comments
• Montreal Portocol agreement finally here-what will it cost?
• More Bad News for Amgen & Ortho
• More Bad News for Disease Management In Medicare
• More Bad News for Epo and It's Fans
• More bells, less to ring about
• More of the Same
• mTOR inhibitors Not Just for Kidney Cancer (RCC)
• Multifocal contact lenses unlikely to impact market for surgical correction
• Multifocal IOLS are In their Infancy
• My opinion
• Nasal steroids for Asthma
• National dental licensure
• NeuroSearch’s ACR16: The Many Faces of a New “Dopamine Stabilizer”
• New agent for PHN
• New alternative to multi-level fusions
• New and improved, but not without potential downside
• New Approaches in Bipolar Disorder
• New Blood Pressure Weapon – “Been there, done that”
• New category of antihypertensive very appealing
• NEW DERMATOLOGICAL TREATMENT RELEAVES RADIATION DERMATITIS
• new device from MIT may prove to be next breakthrough in neurological rehabilitation after stroke
• New device looks promising for improving motor function after stroke
• New drug classes for HIV effective at the margin
• New FDA approval for Keppra (levetiracetam)
• New FDA Indication for Cymbalta
• New Pen, Old technology, More Money
• New Provider Healthcare Pay-for-Performance Ideas
• New Rapid Viral Meningitis Test
• New technology may improve liposuction safety and efficacy
• New therapies needed
• New Therapy for Refractory Prostste Ca?
• New use for anti-tnf medication
• New Vaccine for CMV
• New Vaccine is a positive "baby" step in fight agianst Avian Flu pandemic
• New wrinkle on an old technique
• Newer is better?
• Newly identified risks for refractive surgery
• No Brainer!
• No downtime is king
• No pain, no gain in "Blasting Away Wrinkles"
• No surprise.
• Non-Surgical Nosejob is not a Nosejob and not Risk-free
• Not a surprising development.
• Not all systems work the same way, some are outright dangerous
• Not at all surprizing
• Not exactly what they claim
• Not for general usage
• Not good for MRSA
• Not Good News for Pancreatic Cancer Patients, Erbitux, BMS or ImClone
• Not New News...
• Not so simple to rate doctors
• Nothing New! Impact??
• Novartis The ARB Company-All renin blockade
• Now Hold On!
• Old drug resurrected?
• Old recommendations now validated by randomized trial
• One Size Does Not Fit All Eating Disorders
• One-hour tooth implant system DOES have problems!
• Onsite Disease Mangement Personnel Most Certainly Increase Enrollment
• Options for Treatment of Celiac Disease
• Oral allergy treatment has promise ===> $$$$
• Osteologix and osteoporosis
• OTC Viagra - A Good Thing?
• Ozone as a cure for dental decay?
• P4P great if everyone is on board.
• P4P is good, but performance standards are needed first.
• P4P Really Means Less P for all except Insurance CEO's
• Pancreatic cancer vaccine is novel, but have to wait for clinical trials
• Patients Want Maximum Results with Minimum Downtime
• Pay for performance (P4P) requires consensus
• PDT still a viable alternatvie
• perimenstrual migraine prophylaxis
• Personalized Health Care: The Marriage of Gene Therapy and Health IT
• Pfizer wins again
• Pfizer-type deal could become illegal for US distribution
• PFP; the new panacea? Remeber when HMOs were going to do that
• Pharmacy Benefit Management Institute Recognizes Innovation, This is good.
• Pharmacy Benefits are becoming more popular for Employees & Corporations
• Phase 2 Clinical Trial of Azixa™ in GBMs
• Physician Pay for Performance, P4P, in Medicaid has Some Potential, but the Devil is in the Details
• Plasma for Wrinkles: Possbily Effective, but Early
• Plasma is Hot
• Plasma treatment not very novel
• Plate fixation of the cervical spine has a proven advantage
• Play for perfomance
• Poor Prognosis Multiple Myeloma Profiles Good for............
• Portrait Plasma technology by Rhytec
• Potential Additional Benefit from Rimonabant (Acomplia) Treatment
• Potential Benefit of Rimonabant on Fatty Liver.
• Predicting sudden death risk with T-wave alternans testing: The ALPHA study reported at the 2007 ACC meeting
• Presciption Data and Privacy?
• Prescriber Data sales, drug pricing, drug marketing
• Prescribing Opioids Safely
• Prevent cervical cancer
• Preventing both Hepatitis A and B using an accelerated dosing schedule
• Prevention rules: The eye is window to the body PFE MRK SGP AZN DNA NVS BOL
• Primary Care would welcome "non addictive" painkiller
• Proactive Approaches in Patients with Chronic Illness
• Problems with one hour implants
• Proleukin Use in HIV Disease
• Proleukin: Out of age in favor of Nexavar and Sutent
• Promacta: An oral promising drug for chronic ITP
• PROPER USES OF TOPICAL ANTIBIOTICS, SEE BELOW
• Proposed P4P for Medicaid muddies the waters
• Prostate Cancer - Oh what enough data will reveal!
• Provenge
• PSA velocity will help improve prostate cancer screening
• Putting the money where the money is...
• QMed, Medicare and Special Needs Plans - Are SNPs the Future?
• QualityMetric's Tools are Well Recognized in the Disease Management Industry
• radio-labeled antii-ferritin antibody for relapsed/refractory Hodgkin's Disease
• Ranbaxy's generic Zolpidem
• Rapid meningitis test welcome
• Relieva results are encouraging
• Remicade in pediatric Crohn's Disease
• Results from new study unlikely to boost use of Erythroid stimulating agents
• Results will NOT impact use of Erbitux in Colrectal cancer
• Retrievable filters
• Rhophylac for ITP
• Risk of Depression for Patients with Medical Conditions
• Rivastigmine, Donepezil, etc. help dementia and THUS lead to a decreased need for other psychotropics in these patients
• Roche's lower dose formulations are welcome news, but Flu Vaccines remain essential to effectively thwart a Flu pandemic
• Roche's lower dose preparation of tamiflu will allow for easier stockpiling to prepare for flu pandemic
• Safety still an issue
• Satraplatin Shows Promise but Much Unknown
• Savient's Uricase for Gout
• Scorecards! Get Your Hospital Scorecards Here!
• Sculptra - A Volume Enhancing Injectable Filler
• Second dose of varicella is in the future for all - so what?
• Second Recall for B&L New Contact Lens Disinfectant
• Seeing is Believing
• Senate Bill to Block Ads for New Drugs Contradicts Itself
• Sentinal node detection
• SEXUAL DESIRE INCREASE IN WOMEN BY PILL EXPECTED 2008+
• Silicone Breast Implants Face Hearings in Congress
• Simplicity is best
• Sleeping Pills Still Have a Role
• SLEEPING YOUR WAY THROUGH LIFE
• SLIT -the immunotherapy of the future?
• slt vs alt
• Smart Idea, Incomplete Data, Uncertain Market
• Smooth muscles in asthma
• So there ARE alternatives to HFA bronchodilators
• Someone is Not Going to be Happy!
• Sounds good but will it work better?
• Soy Formulas: Too much hype; Stick with Breast milk!!!
• Specialty hospitals face scrutiny
• Squeaky wheel gets the funding
• Staar is a Weak Performer in Ophthalmology
• Statins for Heart Failure – Not so Fast!
• Statins for prostate ca prevention?
• Stem Cell Debacle May Foretell Chilling Trend in Research Funding
• Stem cells - The Time is Now
• Steroids and lung cancer
• Steroids in ARDS
• Still awaiting outcome data.
• Still issues with titration
• StomaphyX - a novel device for "natural orifice incisional surgery"
• StoneBreaker in France-is it a viable option?
• Straterra is indicated for a sub-population of children and adults wih ADHD
• Strattera benefits are less attentional than unintentional
• Switching from Strattera to Stimulants Common
• Tarceva- a first line indication?
• Tarceva in the Elderly is NOT "Without Major Toxicity"
• TB and HIV
• Tekturna (Aliskiren) - a novel anti-hypertensive with great promise
• The "Ideal" steriod?
• The Antidepressant Market in Children and Adolescents: Heading Up?
• The best Disease Management is PREVENTION
• The Black box warning of the Calcineurin inhibitors is faulty
• The Complicated Web of ADHD and Substance Abuse
• The corporate money pot: FDA and it's intoxication with money and power.
• The Omega-3 EPA and Statins: An Healthy Combination
• The Power of the Internet in Capturing Self-Pay Market
• The trend of dcreased FDA approval of new drugs is here to stay
• Thiamine deficiency will make you forget you had weight-loss surgery
• Time will tell
• Timing is Everything
• TO INCREASE (HER) SEX DRIVE or not to, that is the question!!
• TOPS system is still a long way from becoming a relevant device in the US market
• Torisel is effective in renal cell carcinoma and soon in other cancer types
• Tough Decision
• Transmedics Trial could revolutionize organ transport
• TRIAD HOSPITALS BOUGHT FOR $5.1B IN SURPRISE MOVE
• Triple Reuptake Inhibitors for Depression – the Next Big Gun?
• Triple Reuptake Inhibitors: “Mini” Antidepressants
• Triple therapy for COPD
• Twice a day may be better than once a week.
• Unfortunately not enough data
• United Therapeutics has some work to do
• USB integration: a necessary first step
• Use of prescribing data
• Use opioid painkillers chronically and you will get addicted--no ands or buts
• Vaccination for TB
• Vaccine Therapy for Pancreatic Cancer: Could it Work?
• Vaccine would have a major impact on world health
• Vaccines
• Vectibix + Avastin in First Line Colon Cancer: Toxicity not Efficacy. Bad News for Amgen
• Vectibix + Avastin Inferior Therapy for Stage IV Colon Cancer
• VEGF Trap offers New Approach to fight ocular angiogenesis.
• Venlafaxine XR for Pediatric Generalized Anxiety Disorder
• Virginia to become second state to enforce Gardasil use
• Vistakon/Johnson & Johnson Successfully Sues Ciba for Misrepresenting Consumer Opinion
• Wait and See Before More Serious Action Taken
• Walmart investing in new healthcare IT center
• Watch Out TV: Here Comes the Internet!!
• Welcome addition
• What an interesting finding.
• What are statins not useful for?
• What’s Ahead for Men with Eating Disorders?
• When it rains it pours.
• When one medical procedure has more of one technique is because no one is good
• When Prescribed Appropriately Sleep Medications Can be Very Safe and Effective
• Who should treat the Urological Cancer patient-a private pratice perspective
• Whoops!!!
• Whose performance are we counting?
• Why has this drug not taken off?
• Why would kick-boxing NOT cause brain damage?
• WHY?
• Wiil it be better?
• Will be great if can get to target populations
• Will Bifocal RGP Contact Lens Study Lead to a Decline in Soft Bifocal Contact Lens Wearers?
• Will make life easier for RA patients and others
• WILL ROE. V. WADE FADE INTO THE GHOST OF HISTORY PAST?
• Will Satraplatin Get Approved?
• Will Women Seek Out Flibanserin to Get Sexual Boost?
• Will Women Seek Out Flibanserin to Get Sexual Boost?
• Wine can improve your health
• Wright Medical Group, Inc. Carolina (TM) Jones Fracture System for Foot & Ankle Surgery
• WYETH Oral Methylnaltrexone treatment of opioid-induced constipation NDA Filing expected on time.
• Wyeth's Prevnar becomes WHO's posterchild
• XELOX replacinf FOLFOX? Maybe
• Xenoport: Banking on XP13512 for RLS and Neuropathic Pain
• Xibrom: A potential blockbuster for post-operative eye pain?
• Ximelagatran effective in stroke prevention
• Ximelagatran, the Sacrificial Lamb
• Your Guess is Good as Mine......
• Zelnorm withdrawn for cardiac events - post marketing surveillance can work